Allelic difference in Mhc2ta confers altered microglial activation and susceptibility to α-synuclein-induced dopaminergic neurodegeneration

Neurobiol Dis. 2017 Oct:106:279-290. doi: 10.1016/j.nbd.2017.07.016. Epub 2017 Jul 20.

Abstract

Parkinson's Disease (PD) is a complex and heterogeneous neurodegenerative disease characterized by a progressive loss of dopaminergic neurons in the substantia nigra pars compacta and pathological intracellular accumulation of alpha-synuclein (α-syn). In the vast majority of PD patients, the disease has a complex etiology, defined by multiple genetic and environmental risk factors. Common genetic variants in the human leukocyte-antigen (HLA) region have been associated to PD risk and the carriage of these can double the risk to develop PD. Among these common genetic variants are the ones that modulate the expression of MHCII genes. MHCII molecules encoded in the HLA-region are responsible for antigen presentation to the adaptive immune system and have a key role in inflammatory processes. In addition to cis‑variants affecting MHCII expression, a transactivator encoded by the Mhc2ta gene is the major regulator of MHCII expression. We have previously identified variations in the promoter region of Mhc2ta, encoded in the VRA4 region, to regulate MHCII expression in rats. The expression of MHCII is known to be required in the response to α-syn. However, how the expression of MHCII affects the activation of microglial or the impact of physiological, differential Mhc2ta expression on degeneration of dopaminergic neurons has not previously been addressed. Here we addressed the implications of common genetic allelic variants of the major regulator of MHCII expression on α-syn-induced microglia activation and the severity of the dopaminergic neurodegeneration. We used a viral vector technology to overexpress α-syn in two rat strains; Dark agouti (DA) wild type and DA.VRA4-congenic rats. The congenic strain carries PVG alleles in the VRA4 locus and therefore displays lower Mhc2ta expression levels compared to DA rats. We analyzed the impact of this physiological differential Mhc2ta expression on gliosis, inflammation, degeneration of the nigro-striatal dopamine system and behavioral deficits after α-syn overexpression. We report that allelic variants of Mhc2ta differently modified the microglial activation in response to overexpression of human α-syn in rats. Overexpression of α-syn led to a larger denervation of the nigro-striatal system and significant behavioral deficits in DA.VRA4 congenic rats with lower Mhc2ta expression compared to DA rats. These results indicate that Mhc2ta is a key upstream regulator of the inflammatory response in PD pathology.

Keywords: Alpha synuclein; Dopaminergic neurons; Genetics; Inflammation; MHCII; Mhc2ta; Microglia; Neurodegeneration; Parkinson's disease.

MeSH terms

  • Alleles
  • Animals
  • Corpus Striatum / metabolism
  • Corpus Striatum / pathology
  • Dependovirus / genetics
  • Dopaminergic Neurons / metabolism
  • Dopaminergic Neurons / pathology
  • Genes, MHC Class II
  • Genetic Predisposition to Disease*
  • Genetic Variation
  • Genetic Vectors
  • Humans
  • Male
  • Microglia / metabolism*
  • Microglia / pathology
  • Motor Activity / physiology
  • Nerve Degeneration / genetics
  • Nerve Degeneration / metabolism
  • Nerve Degeneration / pathology
  • Nuclear Proteins / genetics*
  • Nuclear Proteins / metabolism*
  • Parkinsonian Disorders / genetics*
  • Parkinsonian Disorders / metabolism*
  • Parkinsonian Disorders / pathology
  • Rats, Transgenic
  • Trans-Activators / genetics*
  • Trans-Activators / metabolism*
  • alpha-Synuclein / administration & dosage
  • alpha-Synuclein / genetics
  • alpha-Synuclein / metabolism

Substances

  • MHC class II transactivator protein
  • Nuclear Proteins
  • SNCA protein, human
  • Trans-Activators
  • alpha-Synuclein